Dec 15, 2022 4:01 pm EST Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dec 12, 2022 10:00 am EST Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting
Dec 02, 2022 4:01 pm EST Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 23, 2022 8:00 am EST Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference
Nov 08, 2022 4:01 pm EST Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress
Nov 04, 2022 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 01, 2022 4:05 pm EDT Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
Oct 26, 2022 2:01 am EDT Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022
Oct 14, 2022 7:08 am EDT CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease